

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Christine A. WHITE et al.

GAU: 1643

Serial No: 09/436,347

Confirmation No. 6491

Filed: November 9, 1999

Examiner: A. M. Harris

For: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING ANTI-CD20 ANTIBODIES (AS AMENDED)

Request For Continued Examination (RCE) Transmittal

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 C.F.R. § 1.114. Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
 - a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
 - i. ☒ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on May 29, 2009
 - ii. ☒ Other: Declaration Under 37 C.F.R. § 1.132 previously filed on May 29, 2009
 - b. ☒ Enclosed
 - i. ☐ Amendment/Reply
 - ii. ☐ Affidavit(s)/Declaration(s)
 - iii. ☒ Information Disclosure Statement (IDS)
 - iv. ☐ Other: _____
2. Miscellaneous.
 - a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required).
 - b. ☐ Other: _____
3. Fees. The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to:
 - a. ☒ Deposit Account No. 18-1260
 - i. ☒ RCE fee required under 37 C.F.R. 1.17(e)
 - ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
 - iii. ☐ Other:
 - b. ☐ Check in the amount of \$ _____ enclosed.
 - c. ☐ Payment by credit card (Form PTO-2038 enclosed).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Sidley Austin LLP
1501 K. Street, N.W.
Washington, DC 20005
Tel: (202) 736-8000
Fax: (202) 736-8711
Customer No.: 47553

Date: June 29, 2009

Respectfully submitted,

/David L. Devernoe/

David L. Devernoe

Registration No. 50,128